Welcome to MOLOGEN AG

With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Our main focus is on oncology and severe infectious diseases.

We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.

Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need. 

Strategy program "NEXT LEVEL"

DR. MARIOLA SÖHNGEN CEO MOLOGEN AG

• Capital increase and convertible bond with gross proceeds of presumably €16.1 million • Further implementation of the “Next Level” corporate strategy • Advancement of the four clinical studies with the lead product lefitolimod (MGN1703) • Progress in these trials affects financial result • Outlook unchanged for full-year 2016 • First... [more]

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. [more]

Quarterly Statement as at 30 September 2016
Download PDF

Half-year report 2016
Download

Balance as at 30 June 2016 (unaudited; German version only)
Download PDF

Quarterly Statement as at 31 March 2016
Download PDF

Annual Report 2015
Download PDF